PTHS (Pelthos Therapeutics) Revenue: $27.70 Mil (TTM As of Mar. 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $24.33
! 4 Warning Signs
View Full Analysis

What is Pelthos Therapeutics Revenue?

Pelthos Therapeutics PTHS -5.59% 8 Revenue is $27.70 Mil as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Pelthos Therapeutics's revenue for the three months ended in Mar. 2026 was $10.91 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $27.70 Mil. Pelthos Therapeutics's Revenue per Share for the three months ended in Mar. 2026 was $3.29. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $8.62.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Pelthos Therapeutics  (AMEX:PTHS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Pelthos Therapeutics Revenue Related Terms

Pelthos Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Pelthos Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pelthos Therapeutics Revenue Chart

Pelthos Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 16.80

Pelthos Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 7.41 9.39 10.91

PTHS vs CGTX, BDTX, CBUS: Revenue Comparison

For the Biotechnology subindustry, Pelthos Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pelthos Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Pelthos Therapeutics's Revenue falls into.


PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $27.70 Mil mean?
Pelthos Therapeutics (PTHS) has a Revenue of $27.70 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Pelthos Therapeutics and its competitors.
Is Pelthos Therapeutics' Revenue too high?
Pelthos Therapeutics' current Revenue is $27.70 Mil. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' Revenue compare to CGTX and BDTX?
Pelthos Therapeutics' Revenue of $27.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current Revenue is $27.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current Revenue of $27.70 Mil. The current Revenue is $27.70 Mil. Pelthos Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current Revenue is $27.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.33
Price